New drug Y-3 tested in healthy people for first time in the U.S.
NCT ID NCT06770491
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This early-stage study tested a single dose of the experimental drug Y-3 in 20 healthy adults to see if it is safe and how the body processes it. Participants received either 40 mg, 60 mg, or a placebo. The study is complete and focused on gathering basic safety and drug-level information, not on treating any illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tranquil Clinical Research
Webster, Texas, 77598, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Y-3
What could go wrong
This is a very early Phase 1 study with only 20 healthy people. It is designed to check safety and how the drug moves through the body, not to treat any disease. There is no guarantee Y-3 will ever be tested in patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.